Publicaciones en las que colabora con Lucía Gandullo Sánchez (10)

2023

  1. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

    Cancer Letters, Vol. 554

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. HER3 in cancer: from the bench to the bedside

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  3. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

  4. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Generation of antibody‐drug conjugate resistant models

    Cancers, Vol. 13, Núm. 18

  3. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

    Biomedicine and Pharmacotherapy, Vol. 144

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

  2. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies

    EMBO Molecular Medicine, Vol. 12, Núm. 5